Who Attends
The program is designed for all size pharma/biotech companies, academia and investors seeking to enable a patient’s immune system to eradicate cancer.
Biopharma Responsible for
- Cancer Immunotherapy
- Immuno-Oncology
- R&D Innovation & Strategy
- Clinical R&D
- Business Development
- Preclinical and Translational Research
- Biomarkers and Companion Dx
- Early Stage Collaborations
- Clinical Operations
- Strategic Partnerships
- External R&D
- Licensing & Commercial Strategy
Solution Providers
- Diagnostic Testing
- Biomarkers and Companion Dx
- Assay Development
- Next Gen Sequencing
- mRNA / DNA Nucleic Acid Processing
- RNA Sequencing
- Cell Analysis/Manufacturing Platforms
- Liquid Biopsies
- Cancer Genetics
- Immune Monitoring
- Imaging Services
- Flow Cytometry
- Data Analysis/Analytics
- Laboratory Services
- Artificial Intelligence
- CROs/Clinical Trial Design
Investment Community Including
- Investment Firms
- Banks/Financial Institutions
- Venture Capital
- Private Equity
- Foundation Capital
- Analysts
Academia & Research Organizations Focusing on
- Immuno-Oncology / Cancer Immunotherapy
- Oncology
- Immunology
- Cancer Vaccines
- Adoptive T-Cell Therapy
- Preclinical & Clinical R&D
Professionals working in immuno-oncology business units will also benefit.
.png)
.png)
.png)
Networking Opportunities
Partnering/One-on-One Meetings:
• Dedicated partnering tables to connect with fellow industry professionals, investors and KOLs
• Partnering tool to schedule partnering meetings
• Meeting times occur throughout all breaks, lunches and receptions
• Set up multiple meetings per day
• Search other attendee profiles
• Send private message to other attendees
• Dedicated partnering help desk
Scheduled Networking:
• Scheduled morning and afternooon breaks
• Lunches
• Receptions
• Access to the exhibit hall
"IO360° was one of the best immuno-oncology meetings I’ve been to. Kudos! Great speakers and great dialogue!"
- Jim Mansfield, PerkinElmer
2025 Sponsors
